<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Qualigen Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc</link>
<description>Latest news and press releases for Qualigen Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/qualigen-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b42b78dffbe2df113026.webp</url>
<title>Qualigen Therapeutics Inc</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc</link>
</image>
<item>
<title>Invitation to Annual General Meeting Fenix Outdoor International AG</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/invitation-to-annual-general-meeting-fenix-outdoor-international-ag-11</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/invitation-to-annual-general-meeting-fenix-outdoor-international-ag-11</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Invitation to the ordinary General Meeting of Shareholders of Fenix Outdoor International AG The Board of Directors is pleased to invite you to the ordinary</description>
</item>
<item>
<title>Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-4</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-4</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound</description>
</item>
<item>
<title>Roundtable and RYVYL Announce Shareholders Approve Merger, with 99% of Votes Cast in Favor</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/roundtable-and-ryvyl-announce-shareholders-approve-merger-with-99percent-of-votes-cast-in-favor</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/roundtable-and-ryvyl-announce-shareholders-approve-merger-with-99percent-of-votes-cast-in-favor</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), and RTB Digital Inc.’s (Roundtable) CEO, James Heckman,</description>
</item>
<item>
<title>Pulsar Helium Announces Officer Appointment</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/pulsar-helium-announces-officer-appointment-7</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/pulsar-helium-announces-officer-appointment-7</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR</description>
</item>
<item>
<title>Endeavour To Announce Its Q1 2026 Results On 30 April 2026</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/endeavour-to-announce-its-q1-2026-results-on-30-april-2026-7</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/endeavour-to-announce-its-q1-2026-results-on-30-april-2026-7</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>ENDEAVOUR TO ANNOUNCE ITS Q1 2026 RESULTS ON 30 APRIL 2026 London, 2 April 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) expects to release its</description>
</item>
<item>
<title>Acuity Reports Fiscal 2026 Second-Quarter Results</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/acuity-reports-fiscal-2026-second-quarter-results</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/acuity-reports-fiscal-2026-second-quarter-results</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Strong Execution Delivers Sales Growth, Margin Expansion and EPS Improvement Delivered Net Sales of $1.1B, an Increase of 5% Compared to the Prior</description>
</item>
<item>
<title>JDE Peet’s transfers shares to participants under its employee incentive plans</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/jde-peets-transfers-shares-to-participants-under-its-employee-incentive-plans-14</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/jde-peets-transfers-shares-to-participants-under-its-employee-incentive-plans-14</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>PRESS RELEASE Amsterdam, April 2, 2026 This is a press release by JDE Peet’s N.V. (JDE Peet’s or the Company) pursuant to the provisions of section 13,</description>
</item>
<item>
<title>Freight Technologies Announces Strategic Update on Transition to AI-Powered, Software-First Logistics Technology Company</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/freight-technologies-announces-strategic-update-on-transition-to-ai-powered-software-first-logistics-technology-company</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/freight-technologies-announces-strategic-update-on-transition-to-ai-powered-software-first-logistics-technology-company</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Company explores strategic alternatives for online brokerage business, including potential sale, as it accelerates commercialization of proprietary SaaS and</description>
</item>
<item>
<title>Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/priovant-expands-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-4</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/priovant-expands-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-4</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound</description>
</item>
<item>
<title>IDEX Corporation to Webcast First Quarter 2026 Earnings Call</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/idex-corporation-to-webcast-first-quarter-2026-earnings-call</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/idex-corporation-to-webcast-first-quarter-2026-earnings-call</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE:IEX) announced today that it will release its first quarter 2026 results on Wednesday, April 29,</description>
</item>
<item>
<title>InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 02</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/intercontinental-hotels-group-plc-announces-transaction-in-own-shares-april-02-10</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/intercontinental-hotels-group-plc-announces-transaction-in-own-shares-april-02-10</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>InterContinental Hotels Group PLC (the "Company")Purchase of own shares LONDON, UK / ACCESS Newswire / April 2, 2026 / The Company announces that on 01 April</description>
</item>
<item>
<title>Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-5</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-5</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the</description>
</item>
<item>
<title>The Cigna Group's First Quarter 2026 Earnings Release Details</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/the-cigna-groups-first-quarter-2026-earnings-release-details</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/the-cigna-groups-first-quarter-2026-earnings-release-details</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>BLOOMFIELD, Conn., April 2, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2026 financial results on</description>
</item>
<item>
<title>Caledonia Mining Corporation Plc-Issue of Securities Pursuant to Long Term Incentive Plan Awards and Issue of New Long Term Incentive Plan Awards</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/caledonia-mining-corporation-plc-issue-of-securities-pursuant-to-long-term-incentive-plan-awards-and-issue-of-new-long-term-incentive-plan-awards-10</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/caledonia-mining-corporation-plc-issue-of-securities-pursuant-to-long-term-incentive-plan-awards-and-issue-of-new-long-term-incentive-plan-awards-10</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>(NYSE American:CMCL)(AIM:CMCL)(VFEX:CMCL) SAINT HELIER, JE / ACCESS Newswire / April 2, 2026 / Caledonia Mining Corporation Plc ("the Company" or "Caledonia")</description>
</item>
<item>
<title>Hayasa Metals Announces 39m @ 0.50% Cu from Late Season Drill Hole at Urasar; Prospects Update</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/hayasa-metals-announces-39m-050percent-cu-from-late-season-drill-hole-at-urasar-prospects-update</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/hayasa-metals-announces-39m-050percent-cu-from-late-season-drill-hole-at-urasar-prospects-update</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 2, 2026) - Hayasa Metals Inc. (TSXV: HAY) (OTCQB: HAYAF) ("Hayasa" or the "Company") has received the</description>
</item>
<item>
<title>Sigma Lithium Signs with a Major Brazilian Bank a US$100 Million Collateralized Bank Guarantee</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/sigma-lithium-signs-with-a-major-brazilian-bank-a-usdollar100-million-collateralized-bank-guarantee</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/sigma-lithium-signs-with-a-major-brazilian-bank-a-usdollar100-million-collateralized-bank-guarantee</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>SUMMARY Sigma Lithium signs a US$100 Million bank guarantee ("Bank Collateral"), fully collateralized by its clients through a blend of corporate guarantees,</description>
</item>
<item>
<title>Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/costamare-inc-declares-quarterly-dividend-on-its-preferred-and-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/costamare-inc-declares-quarterly-dividend-on-its-preferred-and-common-stock</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MONACO, April 02, 2026 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625%</description>
</item>
<item>
<title>Kraken Robotics Schedules Q4 and Year-End 2025 Financial Results Release and Webcast</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/kraken-robotics-schedules-q4-and-year-end-2025-financial-results-release-and-webcast</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/kraken-robotics-schedules-q4-and-year-end-2025-financial-results-release-and-webcast</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>ST. JOHN'S, Newfoundland and Labrador, April 02, 2026 (GLOBE NEWSWIRE) -- Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF)</description>
</item>
<item>
<title>Cheche Group Reports Second Half and Full Year 2025 Unaudited Financial Results</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/cheche-group-reports-second-half-and-full-year-2025-unaudited-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/cheche-group-reports-second-half-and-full-year-2025-unaudited-financial-results</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform,</description>
</item>
<item>
<title>FF Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/qualigen-therapeutics-inc/news/ff-announces-fourth-quarter-and-full-year-2025-financial-results-8</link>
<guid isPermaLink="true">https://6ix.com/company/qualigen-therapeutics-inc/news/ff-announces-fourth-quarter-and-full-year-2025-financial-results-8</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>LOS ANGELES, April 2, 2026 /PRNewswire/ -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("FF," "Faraday Future," or the "Company"), a</description>
</item>
</channel>
</rss>